Bionano Genomics, Inc. Q3 2025 Earnings Recap

BNGO Q3 2025 November 14, 2025

Get alerts when BNGO reports next quarter

Bionano reported a strong third quarter in 2025, achieving $7.4 million in revenue, representing a 21% year-over-year increase, driven by higher utilization among routine users of its optical genome mapping solutions.

Earnings Per Share Beat

$-1.59 vs $-1.81 est.

+12.2% surprise

Revenue Miss

7367000 vs 7900000 est.

-6.7% surprise

Market Reaction

1-Day +3.4%

5-Day +4.76%

30-Day +12.93%

See BNGO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue rose 21% year-over-year, with core revenues up 12% after adjusting for discontinued services.
Non-GAAP gross margin improved significantly to 46%, up from 26% in Q3 2024.
Non-GAAP operating expenses decreased 40% year-over-year to $9.7 million, showcasing effective cost management.
Sold a record 8,390 flow cells, reflecting 7% growth and increased utilization by existing customers.
Cash position strengthened to $31.8 million following a $10 million public offering, extending the cash runway into 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BNGO on AllInvestView.

Previous Q2 2025

Next Q1 2026